Key result
Pulmonary hypertension is a commonly encountered comorbidity in patients with chronic kidney disease and end-stage renal disease, with estimated prevalence up to 56%.
Pulmonary hypertension is a frequently encountered comorbidity in patients with CKD and ESRD, requiring careful hemodynamic evaluation.
Requires careful hemodynamic evaluation in CKD/ESRD; leaves open optimal PH-targeted interventions pending prospective data.
Chronic kidney disease (CKD) is a common condition and its prevalence is increasing.12 Likewise, the number of patients reaching end-stage renal disease (ESRD) continues to rise. In the United States in 2010, there were 413,275 patients on dialysis and 179,361 patients with a functioning renal transplant, bringing the rate of prevalent ESRD cases to 1752 per million population.2 Pulmonary hypertension (PH) is a commonly encountered comorbidity of patients with CKD and those who have progressed to ESRD. Although the true prevalence of PH in these populations is unknown, several small, single-center analyses using varied cutoffs for echocardiographically estimated pulmonary pressures have reported estimates as high as 56%.3–7
No takes yet. Share an insight, caveat, or question.
Tedford et al. (2013) conducted a review in Pulmonary Hypertension in Chronic Kidney Disease. Pulmonary hypertension is a commonly encountered comorbidity in patients with chronic kidney disease and end-stage renal disease, with estimated prevalence up to 56%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: